Substituted piperazines as cb1 antagonists

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 241/04 (2006.01) A61K 31/496 (2006.01) A61K 31/506 (2006.01) A61P 3/00 (2006.01) A61P 9/10 (2006.01) C07D 401/06 (2006.01)

Patent

CA 2694253

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

L'invention porte sur des composés représentés par la Formule (I) ou des sels, solvates ou esters pharmaceutiquement acceptables de ces composés, qui sont utiles dans le traitement de maladies ou états à médiation par des récepteurs de CB1, tels que le syndrome métabolique et l'obésité, les troubles neuro-inflammatoires, les troubles cognitifs et la psychose, la toxicomanie (par exemple le sevrage tabacologique), les troubles gastro-intestinaux et les états cardio-vasculaires.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Substituted piperazines as cb1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted piperazines as cb1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazines as cb1 antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1430519

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.